Amylin And Takeda Team Up In Obesity

Two potentially important mid-stage programs in the obesity research space are off the partnering table with the announcement Nov. 1 that Takeda and Amylin have teamed up to develop and commercialize several obesity candidates, including pramlintide/metreleptin and davalintide

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip